company background image
DTIL

Precision BioSciences NasdaqGS:DTIL Stock Report

Last Price

US$2.06

Market Cap

US$228.3m

7D

28.0%

1Y

-78.3%

Updated

15 Aug, 2022

Data

Company Financials +
DTIL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

DTIL Stock Overview

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States.

Precision BioSciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Precision BioSciences
Historical stock prices
Current Share PriceUS$2.06
52 Week HighUS$14.38
52 Week LowUS$1.11
Beta1.56
1 Month Change45.07%
3 Month Change9.00%
1 Year Change-78.32%
3 Year Change-78.89%
5 Year Changen/a
Change since IPO-88.19%

Recent News & Updates

Aug 05

Precision BioSciences Q2 2022 Earnings Preview

Precision BioSciences (NASDAQ:DTIL) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open. The consensus EPS Estimate is -$0.46 (-227.8% Y/Y) and the consensus Revenue Estimate is $5.11M (-92.6% Y/Y). Over the last 3 months, EPS estimates have seen 3 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Shareholder Returns

DTILUS BiotechsUS Market
7D28.0%1.4%3.6%
1Y-78.3%-19.6%-9.6%

Return vs Industry: DTIL underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: DTIL underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is DTIL's price volatile compared to industry and market?
DTIL volatility
DTIL Average Weekly Movement18.2%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: DTIL is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: DTIL's weekly volatility has increased from 13% to 18% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006192Michael Amorosohttps://www.precisionbiosciences.com

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.

Precision BioSciences, Inc. Fundamentals Summary

How do Precision BioSciences's earnings and revenue compare to its market cap?
DTIL fundamental statistics
Market CapUS$228.29m
Earnings (TTM)-US$92.77m
Revenue (TTM)US$37.51m

6.1x

P/S Ratio

-2.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DTIL income statement (TTM)
RevenueUS$37.51m
Cost of RevenueUS$0
Gross ProfitUS$37.51m
Other ExpensesUS$130.28m
Earnings-US$92.77m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.84
Gross Margin100.00%
Net Profit Margin-247.31%
Debt/Equity Ratio21.5%

How did DTIL perform over the long term?

See historical performance and comparison